OncoMatch/Clinical Trials/NCT02691923
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
Is NCT02691923 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Fluorescein and Fluorescein + ALA for brain cancer.
Treatment: Fluorescein · Fluorescein + ALA — This clinical research will evaluate the diagnostic potential of fluorescein as visualized through an operating microscope relative to 1) contrast enhancement on co-registered preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard histology obtained from biopsy sampling during the procedure. Subjects will include those people with operable brain tumor with first-time presumed pre-surgical diagnosis of high-grade glioma or low-grade glioma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Lab requirements
Kidney function
Serum creatinine ≤ 180µmol/L (2.04 mg/dL) within 30 days prior to surgery.
Liver function
No history of liver disease within the last 12 months. AST, ALT, ALP or bilirubin levels must be ≤ 2.5 times the normal limit within 30 days prior to surgery.
History of liver disease within the last 12 months [excluded]. Elevated LFTs (AST, ALT, ALP or bilirubin levels greater than 2.5 times the normal limit) from laboratory tests conducted within 30 days prior to surgery [excluded]. Serum creatinine in excess of 180µmol/L (2.04 md/dL) within 30 days prior to surgery [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sally B Mansur · Lebanon, New Hampshire
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02691923 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages